CTCs
Circulating Tumor Cells Could Be Key to Noninvasive PD-L1 Tracking in Small Cell Lung Cancer
Premium
Early research suggests size-based sorting of circulating tumor cells may open new avenues for blood-based PD-L1 expression analysis in SCLC patients.
Plus Therapeutics, Biocept Ink Lab Services Agreement for ReSPECT-LM Trial
Biocept will test patients with its CNSide cerebrospinal fluid cell capture assay to evaluate responses to Plus' radiotherapy drug candidate.
BioMark Diagnostics, Icahn Mount Sinai to Develop Multiomic Lung Cancer Tests
The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics.
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Rarecells Raises $13M in Series A Round to Develop Liquid Biopsy Early Cancer Detection Tests
The company is planning to develop circulating tumor cell assays for prostate cancer and acute myeloid leukemia and to launch them in the US.
Aug 18, 2021
Mar 31, 2021
Sep 10, 2020
May 21, 2019
May 7, 2019
Genomic Health Q1 Revenues Up 17 Percent
May 16, 2018